R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca's Imfinzi fails main OS endpoint in PhIII for head and neck cancer — and adding tremelimumab didn’t help, either

5 years ago

Roche chops TNBC programs following PhIII flops, further dimming the spotlight on Array drug

5 years ago

Biogen sweeps out a Parkinson’s drug on PhII failure as analysts raise alarms about projected revenue slide — despite assuming an aducanumab OK

5 years ago

Eager to redeem its Covid-19 vaccine, AstraZeneca touts 82.4% efficacy for 12-week dosing schedule — but will the FDA buy it?

5 years ago

Amgen scraps or halts a slate of 5 cancer studies in a series of setbacks. But execs focus on mastering 'induced proximity'

5 years ago

Martin Shkreli’s old company touts PhIII win, guns for accelerated approval

5 years ago

Two years after flop, Verona gets a win as it preps for pivotal Phase III trials

5 years ago

Eli Lilly's new cancer R&D chief has some things to say about drug discovery, the difficulty in finding new drugs to buy and the Venn dilemma

5 years ago

Immunovant voluntarily halts studies on sole drug after surprise cholesterol findings, FcRn rival argenx surges

5 years ago

Bristol Myers flags another PhIII success for one of their top blockbuster prospects, clearing a path to the FDA

5 years ago

Arcutis showcases positive PhIII data showing its topical cream scratched the sweet spot Otezla or steroids couldn't

5 years ago

WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer

5 years ago

J&J pushes new amivantamab data for NSCLC subset, trying to bolster case for quick FDA approval

5 years ago

Amgen showcases its last big round of promising KRAS G12C data for sotorasib. Next up: A likely marketing campaign for a breakthrough therapy

5 years ago

Medigene cuts TCR-T therapy in pivot to focus on solid tumors

5 years ago

ARCH announces largest fund yet, raising $1.85B to back mental health, cell and gene editing approaches

5 years ago

Top gene therapy deals, M&A pacts in 2020 highlight another big year in one of the hottest fields in biopharma

5 years ago

Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag

5 years ago

BeiGene's PD-1 scores PhIII win in esophageal cancer — a 'key indication' tapped by Novartis in $650M deal

5 years ago

Pfizer's big blockbuster Xeljanz flunks its post-marketing safety study, renewing harsh questions for JAK class

5 years ago

AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio

5 years ago

Agios scores its second positive round of data for its lead pipeline drug — but that won't answer the stubborn questions that surround this program

5 years ago

Vir's CMO says he's surprised that a low dose of their hepatitis B drug appears promising in early slice of data — shares soar

5 years ago

Myovant beefs up data package in NDA #3, boosting its case for longterm dosing of Pfizer-partnered relugolix

5 years ago

First page Previous page 177 178 179180181 182 183 Next page Last page